CGON — CG Oncology, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1991792 ·
Last close
$67.15
Market Cap
$5.95B
52W High
$80.97
52W Low
$35.80
ADV30
830,857
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,157,000 | -2,768,000 | -86,401,000 | -79,056,000 | 1,085,655,000 | 19,636,000 | 56,537,000 |
| Mar 2026 | 1,083,000 | -1,879,000 | -66,389,000 | -60,202,000 | 1,135,262,000 | 33,700,000 | 43,483,000 |
| Dec 2025 | 2,322,000 | -748,000 | -48,700,000 | -41,309,000 | 791,592,000 | 32,490,000 | 38,990,000 |
| Sep 2025 | 1,666,000 | 89,000 | -51,129,000 | -43,808,000 | 729,913,000 | 45,145,000 | 42,270,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-178,467,000
Investing CF
$-364,877,000
Financing CF
$548,356,000
CapEx
$-876,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.72
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-518,234,000
Inventory
$1,003,000
Receivables
$417,000
ST Investments
$1,008,642,000
EBIT TTM
$-252,619,000
Pretax Income TTM
$-224,375,000
Interest Exp TTM
—
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,228,000
EBITDA
$-249,663,008
Free Cash Flow
$-113,709,872
Enterprise Value
$5,393,672,192
Total Cash
$1,028,278,016
Total Debt
$8,819,000
Shares Out
88,640,375
Trailing EPS
$-2.69
Book Value
$11.65
ROE
-26.4%
ROA
-17.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,040,000 | -190,774,000 | -160,995,000 | 791,592,000 | 38,990,000 | 752,602,000 | -132,346,000 |
| Dec 2024 | 1,139,000 | -114,666,000 | -88,039,000 | 754,797,000 | 21,420,000 | 733,377,000 | -78,713,000 |
| Dec 2023 | 204,000 | -55,449,000 | -48,607,000 | 199,301,000 | 14,511,000 | 184,790,000 | -45,679,000 |
| Dec 2022 | 191,000 | -35,246,000 | -35,443,000 | 147,747,000 | 22,570,000 | 125,177,000 | -29,804,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.02
Max Pain — expiry 2026-10-16
max pain strike: $70.00 · spot: $66.82 · call oi: 8,172 · put oi: 2,447
Expected Move to 2026-10-16:
±$7.95
(11.90%) —
implied range
$58.87 –
$74.77
· ATM straddle on $65.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SRRK | Scholar Rock Holding Corp | $5.92B | $48.63 | — |
| CRSP | CRISPR Therapeutics AG | $5.24B | $54.23 | — |
| IMVT | Immunovant, Inc. | $6.88B | $33.30 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $4.98B | $11.00 | — |
| ADPT | Adaptive Biotechnologies Corp | $4.70B | $29.43 | — |
News headlines (Yahoo Finance, 1h cache)
CG Oncology (CGON) Stock Looks Fully Priced After A 160% Run
2026-09-03 13:06 · Yahoo
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
2026-08-26 14:41 · Yahoo
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 12:15 · Yahoo
CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology
2026-07-27 22:45 · Yahoo
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
2026-07-13 13:03 · Yahoo
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing Ahead
2026-06-10 07:02 · Yahoo
CG Oncology Touts Cretostimogene Data, BLA Progress in Bladder Cancer Push
2026-06-07 21:05 · Yahoo
Did CG Oncology’s Leadership Consolidation Around CEO Kuan Just Shift CGON’s Commercialization Narrative?
2026-05-31 21:08 · Yahoo
CG Oncology to Present at Upcoming Investor Conferences in June
2026-05-28 20:05 · Yahoo
3 Stocks Call Traders Are Targeting Today
2026-09-11 15:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.